IP Library Granted Patent US 12,029,743
Granted Patent B2
US 12,029,743 · App. 16/350,559 · Granted Jul 9, 2024

Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort

Inventor: Edward T. Wei (Berkeley, CA)
A61K31/66A61K9/0014A61K9/0053A61K9/06A61K9/08A61K9/12A61K47/10A61P17/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,029,743
App. No.
16/350,559
Granted
Jul 9, 2024
Kind
B2
Abstract

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of dermatological disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; atopic dermatitis; contact dermatitis; cholestatic itch; psoriasis; sebhorrheic dermatitis; milaria rubra; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates skin discomfort. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy of dermatological disorders.

Claims (20)

1. A therapeutic method for the treatment of itch caused by a skin dysesthesia in a subject in need of treatment thereof, comprising:

topically applying a semi-liquid composition to keratinized tissues of the subject's skin, the composition comprising a therapeutically effective amount of one or more compound having Formula 1

wherein R is n-heptyl, n-octyl or n-nonyl;

and wherein the composition, following topical application, penetrates the keratinized tissues of the subject's skin.

2. The method as in claim 1 wherein the composition has from about 0.05 to 2% by weight of the Formula 1 compound.

3. The method as in claim 1 wherein the Formula 1 compound is 1-diisopropyl-phosphinoyl-heptane (DIPA-1-7), 1-diisopropyl-phosphinoyl-octane (DIPA-1-8) or 1-diisopropyl-phosphinoyl-nonane (DIPA-1-9) and the therapeutically effective amount is from about 1 to 20 mg/ml.

4. A method for the treatment of dermatitis in a subject in need of treatment thereof, the method comprising:

topically applying a liquid or semi-liquid composition to keratinized tissues of the subject's skin, the composition having comprising a therapeutically effective amount of one or more compounds having Formula 1

wherein R is n-heptyl, n-octyl or n-nonyl; and

wherein the liquid or semi-liquid composition, following topical application, penetrates the keratinized tissues of the subject's skin.

5. The method of claim 4 wherein the dermatitis is atopic dermatitis.

6. The method of claim 4 wherein the dermatitis is contact dermatitis.

7. The method of claim 4 wherein the liquid or semi-liquid composition has from about 0.05 to 2% by weight of the Formula 1 compound.

8. The method of claim 4 wherein the Formula 1 compound is 1-diisopropyl-phosphinoyl-heptane (DIPA-1-7), 1-diisopropyl-phosphinoyl-octane (DIPA-1-8), and/or 1-diisopropyl-phosphinoyl-nonane (DIPA-1-9), and the therapeutically effective amount is from 1-20 mg/ml.

9. A method for the treatment of pruritus in a subject in need of treatment thereof, the method comprising:

topically applying a liquid or semi-liquid composition to keratinized tissues of the subject's skin, the composition having comprising a therapeutically effective amount of one or more compounds having Formula 1

wherein R is n-heptyl, n-octyl or n-nonyl; and

wherein the liquid or semi-liquid composition, following topical application, penetrates the keratinized tissues of the subject's skin.

10. The method of claim 9 wherein the liquid or semi-liquid composition has from about 0.05 to 2% by weight of the Formula 1 compound.

11. The method of claim 9 wherein the Formula 1 compound is 1-diisopropyl-phosphinoyl-heptane (DIPA-1-7), 1-diisopropyl-phosphinoyl-octane (DIPA-1-8), and/or 1-diisopropyl-phosphinoyl-nonane (DIPA-1-9), and the therapeutically effective amount is from 1-20 mg/ml.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2024
From: WEI, EDWARD T.
To: IVIEW THERAPEUTICS, INC.
Reel/Frame 067536/0565 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2022
From: IVIEW THERAPEUTICS, INC.
To: WEI, EDWARD T.
Reel/Frame 059688/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2021
From: ORINDA PHARMA, INC.
To: IVIEW THERAPEUTICS, INC.
Reel/Frame 055859/0145 →
Continuity (2)
Continuation In Part 14544355 · Dec 29, 2014
Related Publication 20190105335A1 · Apr 11, 2019